Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild
Executive Summary
A successor to the anti-epileptic Felbatol is among the development projects for Carter-Wallace's healthcare unit following its acquisition by an investment firm run by former Warner-Lambert exec Anthony Wild.
You may also be interested in...
MedPointe gears up for product acquisitions
MedPointe will use $70 mil. from sale of Wampole diagnostics division to acquire additional pharmaceutical products. The company is considering respiratory and pediatric products with annual sales of $30 mil. to $100 mil. to complement its existing portfolio; one or more deals could be announced by the end of the year. MedPointe, lead by former Warner-Lambert exec Anthony Wild, acquired Wampole when it purchased Carter-Wallace's healthcare business in October 2001 (1"The Pink Sheet" May 14, 2001, p. 13). The cash sale of Wampole to Inverness is expected to close in September...
MedPointe gears up for product acquisitions
MedPointe will use $70 mil. from sale of Wampole diagnostics division to acquire additional pharmaceutical products. The company is considering respiratory and pediatric products with annual sales of $30 mil. to $100 mil. to complement its existing portfolio; one or more deals could be announced by the end of the year. MedPointe, lead by former Warner-Lambert exec Anthony Wild, acquired Wampole when it purchased Carter-Wallace's healthcare business in October 2001 (1"The Pink Sheet" May 14, 2001, p. 13). The cash sale of Wampole to Inverness is expected to close in September...
MedPointe expands sales force with Innovex
Quintiles contract sales subsidiary Innovex will recruit and train 120 sales reps for MedPointe. The additional force increases MedPointe's total sales reps to 300 and expands the number of primary care doctors called on from 28,000 to 50,000. Training will focus on the antihistamine nasal spray Astelin and cold products Ryna/Tussi; recruitment should be completed by March. Medpointe, lead by former Warner-Lambert exec Anthony Wild, acquired Carter-Wallace's prescription business in October (1"The Pink Sheet" May 14, 2001, p. 13)...